| Title |
Antiangiogenic therapy combined with immune checkpoint blockade in renal cancer
|
|---|---|
| Published in |
Angiogenesis, April 2017
|
| DOI | 10.1007/s10456-017-9550-0 |
| Pubmed ID | |
| Authors |
Teele Kuusk, Laurence Albiges, Bernard Escudier, Nikolaos Grivas, John Haanen, Thomas Powles, Axel Bex |
| Abstract |
Antiangiogenic therapy with vascular endothelial growth factor (VEGF) inhibitors is the current first-line treatment in metastatic renal cell carcinoma (mRCC). Immunotherapy with checkpoint inhibitor has been recently added to the armamentarium of mRCC treatment. These therapies are based on treatment with antibodies that block programmed cell death-1 (PD-1), programmed cell death ligand 1 (PD-L1) pathways, demonstrating impressive response rates and improved survival in several tumour types. So far, nivolumab is the only approved anti-PD-1 monoclonal antibody after VEGF therapy in mRCC. According to preclinical and clinical studies, combination therapies with VEGF- and checkpoint inhibitors have synergistic effect achieving improved response rates. However, toxicity in some combinations is high. In this article, we present a review of the ongoing trials with these drug combinations for RCC. |
X Demographics
The data shown below were collected from the profiles of 2 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Netherlands | 1 | 50% |
| Unknown | 1 | 50% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 2 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 68 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 68 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 13 | 19% |
| Student > Bachelor | 8 | 12% |
| Student > Ph. D. Student | 6 | 9% |
| Student > Master | 6 | 9% |
| Professor | 3 | 4% |
| Other | 11 | 16% |
| Unknown | 21 | 31% |
| Readers by discipline | Count | As % |
|---|---|---|
| Biochemistry, Genetics and Molecular Biology | 15 | 22% |
| Medicine and Dentistry | 12 | 18% |
| Pharmacology, Toxicology and Pharmaceutical Science | 4 | 6% |
| Agricultural and Biological Sciences | 4 | 6% |
| Immunology and Microbiology | 4 | 6% |
| Other | 5 | 7% |
| Unknown | 24 | 35% |
Attention Score in Context
This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 August 2017.
All research outputs
#17,886,132
of 22,963,381 outputs
Outputs from Angiogenesis
#383
of 538 outputs
Outputs of similar age
#221,349
of 310,118 outputs
Outputs of similar age from Angiogenesis
#8
of 9 outputs
Altmetric has tracked 22,963,381 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 538 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.4. This one is in the 25th percentile – i.e., 25% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 310,118 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 23rd percentile – i.e., 23% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one.